# Phase I Study PK Study With OXP005 and Naprosyn

> **NCT02351024** · PHASE1 · COMPLETED · sponsor: **Oxford Pharmascience Ltd**

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** OXP005
- **DRUG:** Naprosyn®

## Key facts

- **NCT ID:** NCT02351024
- **Lead sponsor:** Oxford Pharmascience Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** — (—)
- **Last updated:** 2015-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02351024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02351024, "Phase I Study PK Study With OXP005 and Naprosyn". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02351024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*